<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000831</url>
  </required_header>
  <id_info>
    <org_study_id>H09-02749</org_study_id>
    <nct_id>NCT01000831</nct_id>
  </id_info>
  <brief_title>Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children</brief_title>
  <official_title>PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine After One andTtwo Doses in Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PHAC/CIHR Influenza Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness (immune response) to one
      or two doses of adjuvanted H1N12009 influenza vaccine in young children. An adjuvant is an
      additive that can boost the immune response. The study will enroll 300 children (ages 6-35
      months). Participants will receive 2 doses of adjuvanted H1N12009 vaccine 3 weeks apart.
      Study procedures include: medical history, blood samples and completing a memory aid.
      Participants will be involved in study related procedures for approximately 6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine if one or two doses of the H1N12009 influenza vaccine
      are needed in young children, a population group at high risk of influenza infection and
      subsequent hospitalization.

      The objectives of this study are two-fold:

        1. To compare the safety and immunogenicity of 1 and 2 doses of adjuvanted H1N12009
           influenza vaccine in children 6-35 months of age.

        2. To conduct the trial soon after the vaccines become available and share the observations
           with health officials and the public as soon as possible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and immunogenicity of one and two doses Arepanrix</measure>
    <time_frame>Day 7 and Day 21 post vaccination measured at day 42</time_frame>
    <description>To compare the safety and immunogenicity of one and two doses of adjuvanted H1N12009 pandemic vaccine in children 6-35 months of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid Trial</measure>
    <time_frame>Day 42</time_frame>
    <description>To conduct this trial soon after the vaccines become available and share observations with health officials and the public as soon as possible</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adjuvanted Arepanrix 2 doses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adjuvanted Arepanrix</intervention_name>
    <description>Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart</description>
    <arm_group_label>Adjuvanted Arepanrix 2 doses</arm_group_label>
    <other_name>Influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent provided for the subject by a parent or legal guardian

          -  Children age 6-35 months

        Exclusion Criteria:

          -  Allergies to eggs, thimerosal, gentamicin sulphate or latex

          -  Life-threatening reaction to previous Flu vaccine

          -  Bleeding disorder

          -  Pregnancy

          -  Receipt of blood or blood products in past 3 months

          -  Chronic illness that could interfere with trial participation

          -  Compromised immune system

          -  Previous lab-confirmed H1N12009 infection

          -  Receipt of H1N12009 vaccine

          -  Receipt of Seasonal Influenza vaccine since March 2009
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Scheifele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Dionne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unité de Recherche en Santé Publique (CHUQ)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center - Vaccine Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Langley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Canadian Center for Vaccinology, Dalhousie University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otto Vanderkooi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alberta Children's Hospital, University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Dobson, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Children's Hospital, University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child and Family Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Center, University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology, Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center - Vaccine Study Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Recherche en Santé Publique (CHUQ)</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J. 2011 May;30(5):402-7. doi: 10.1097/INF.0b013e3182068f33.</citation>
    <PMID>21178654</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>influenza</keyword>
  <keyword>H1N1 influenza vaccine</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>Arepanrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

